Gotham__Org Gotham White.png
FACT-Hep

Functional Assessment of Cancer Therapy – Hepatobiliary

For patients with Hepatobiliary cancer (liver, bile duct and pancreas)

 

Overview

Below are the details for the FACT-Hep measure:

MEASURE NAME:

Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep)

VERSION:

4

NUMBER OF ITEMS:

45

PATIENT POPULATION:

Hepatobiliary cancer patients 18 years and older

RECALL PERIOD:

Past 7 days

RESPONSE SCALE:

5 point Likert-type scale

DATA COLLECTION:

Paper and electronic

ADMINISTRATION:

Self-administration and interview when applicable

SUBSCALE DOMAINS:

Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Hepatobiliary Cancer Subscale

TIME FOR COMPLETION:

10-15 minutes

SCORING:

Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available.

RELATED MEASURES:

Language Availability

Available translations of the FACT-Hep can be obtained by registering for permission. Users are not permitted to translate the FACT-Hep without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Hep may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

 
 

Licensing

Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

 

Selected References

Heffernan, N., Cella, D., Webster, K., Odom, L., Matone, M., Passik, S., Bookbinder, M., Fong, Y., Jarnagin, W., & Blumgart, L.  Measuring health-related quality of life in patients with Hepatobiliary Cancers: The Functional Assessment of Cancer Therapy – Hepatobiliary (FACT-Hep) questionnaire. Journal of Clinical Oncology 2002; 20(9): 2229-2239. doi: 10.1200/JCO.2002.07.093.


Salem, R., Gilbertsen, M., Butt, Z., Memon, K., Vouche, M., Rickey, R., Bakers, T., Abecassis, M., Atassi, R., Riaz, A., Cella, D., Burns, J., Larson, A., Benson, A., Mulcahy, M., Kulik, L., & Lewandowski, R. Prospective quality-of-life study in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.  Clinical Gastroenterology and Hepatology 2013; 11(10): 1358-1365. doi: 10.1016/j.cgh.2013.04.028.


Steel, J., Nadeau, K., Olek, M., & Carr, B. Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma.  Journal of Psychosocial Oncology 2007; 25(3): 19-42.  doi: 10.1300/J077v25n03_02.


Steel, J., Eton, D., Cella, D., Olek, M., & Carr, B. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma.  Annals of Oncology 2006; 17: 304-312. doi:10.1093/annonc/mdj072.


Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.


Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.


Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.


Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

 

Related Measures

FHSI

Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 8 Item Version

NFHSI-18

National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 18 Item Version

FACT-Ga

Functional Assessment of Cancer Therapy – Gastric

Gotham__Group-Gotham-White_SFW.png
Lauren Lent, DHA, MS
President, FACITtrans, LLC
Executive Director, FACIT.org
About Us
© 2020 FACIT.org 
Benjamin Arnold, MA
Executive Director, FACITtrans, LLC
Jason Bredle, MFA
Director, FACIT.org